Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4‐sclerosing cholangitis: Based on a Japanese nationwide study
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16066 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Kensuke Kubota und 12 weiteren Autor:innen. Beteiligte Einrichtung: Endoscopic Unit, Yokohama City University Hospital, Yokohama, Japan. Hauptthemen laut MEDLINE: Cholangitis, Sclerosing, Neoplasms, Glucocorticoids, Immunoglobulin G4-Related Disease. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Objective
IgG4‐related sclerosing cholangitis (IgG4‐SC) is recognized as a benign steroid‐responsive disease; however, little is known about the risk of development of cancer in patients with IgG4‐SC and about how to counter this risk.
Design
We conducted a retrospective review of the data of 924 patients with IgG4‐SC selected from a Japanese nationwide survey. The incidence, type of malignancy, and risk of malignancy in these patients were examined. Then, the standardized incidence ratio (SIR) of cancer in patients with IgG4‐SC was calculated.
Results
Relapse was recognized in 19.7% (182/924) of patients, and cancer development was noted in 15% (139/924) of patients. Multivariate analysis identified only relapse as an independent risk factor for the development of cancer. In most of these patients with pancreato‐biliary cancer, the cancer developed within 8 years after the diagnosis of IgG4‐SC. The SIR for cancer after the diagnosis of IgG4‐SC was 12.68 (95% confidence interval [CI] 6.89–8.79). The SIRs of cancers involving the biliary system and pancreas were 27.35 and 18.43, respectively. The cumulative survival rate was significantly better in the group that received maintenance steroid treatment (MST) than in the group that did not; thus, MST influenced the prognosis of these patients.
Conclusion
Among the cancers, the risk of pancreatic and biliary cancers is the highest in these patients. Because of the elevated cancer risk, surveillance after the diagnosis and management to prevent relapse are important in patients with IgG4‐SC to reduce the risk of development of cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Endoscopic Unit, Yokohama City University Hospital, Yokohama, Japan.
- Department of Internal Medicine, Tokyo Metropolitan, Komagome Hospital, Tokyo, Japan.
- Department of Gastroenterology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
- Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.
- Faculty of Medical Technology, Teikyo University, Tokyo, Japan.
- Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, Japan.
ORCID-Profile: Kensuke Kubota, Atsushi Tanaka, Itaru Naitoh
Zitieren
APA
Kubota, K., Kamisawa, T., Nakazawa, T., Tanaka, A., Naitoh, I., Kurita, Y., Takikawa, H., Unno, M., Kawa, S., Masamune, A., Nakamura, S., Okazaki, K., & Collaborators (2023). Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4‐sclerosing cholangitis: Based on a Japanese nationwide study. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16066
Vancouver
Kubota K, Kamisawa T, Nakazawa T, Tanaka A, Naitoh I, Kurita Y, et al. Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4‐sclerosing cholangitis: Based on a Japanese nationwide study. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16066
BibTeX
@article{Kubota2023,
author = {Kubota, Kensuke and Kamisawa, Terumi and Nakazawa, Takahiro and Tanaka, Atsushi and Naitoh, Itaru and Kurita, Yusuke and Takikawa, Hajime and Unno, Michiaki and Kawa, Shigeyuki and Masamune, Atsushi and Nakamura, Seiji and Okazaki, Kazuichi and Collaborators, Collaborators},
title = {Reducing relapse through maintenance steroid treatment can decrease the cancer risk in patients with IgG4‐sclerosing cholangitis: Based on a Japanese nationwide study},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16066}
}
EUVIMED